Dr. Malcolm Young is a Clinical Pharmacology consultant with more than 30 years of pharmaceutical industry experience, including senior roles at GSK (GlaxoSmithKline) and Indivior. At GSK, he led and supported drug development programs across multiple therapeutic areas, including metabolic diseases, neuroscience, and gastrointestinal conditions, contributing to the regulatory approval and registration of numerous medicines. At Indivior, Dr. Young focused on Clinical Pharmacology and drug development in opioid use disorder and schizophrenia, including the development and regulatory registration of innovative long-acting formulations such as SUBLOCADE® (buprenorphine extended-release injection) and PERSERIS® (risperidone extended-release injectable suspension). His experience encompasses both novel chemical entity (NCE) development and reformulation programs.

Dr. Young provides expertise in Clinical Pharmacology strategy, pharmacokinetic and pharmacodynamic evaluation, drug development, and regulatory strategy, with experience spanning early development through regulatory submission and product registration. Across his career, he has contributed to the regulatory approval and registration of 15 medicines. He is a long-standing member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and has served as a reviewer for leading Clinical Pharmacology journals, including Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology, Obesity and Metabolism, and Clinical Pharmacokinetics.